Novel Agent May Be Game-Changer in Rare Genetic Disease Novel Agent May Be Game-Changer in Rare Genetic Disease
Patients with von Hippel-Lindau face a high risk of renal cell carcinoma and other cancers, which often require multiple surgeries. A new drug may change the course of the disease.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 1, 2021 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news

FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer
This is the first immunotherapy to be approved for adjuvant use in intermediate- or high-risk patients with renal cell carcinoma after surgery.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma
On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 17, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Liver Cancer Risk Lingers Even After HCV Eradication Liver Cancer Risk Lingers Even After HCV Eradication
Risk for hepatocellular carcinoma (HCC) is lower for patients who have sustained viral responses after drug therapy for hepatitis C, but this treatment does not cure fibrosis, a common cause of HCC.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 17, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Commissioning policy - stereotactic ablative body radiotherapy
Stereotactic ablative body radiotherapy (SABR) is recommended as a treatment option through routine commissioning for adults with locally advanced, inoperable, non-metastatic pancreatic carcinoma (LANPC) within the criteria set out in this policy statement. (Source: NHS Networks)
Source: NHS Networks - November 9, 2021 Category: UK Health Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Is the Most Common Type of Renal Cell Carcinoma?
Title: What Is the Most Common Type of Renal Cell Carcinoma?Category: Diseases and ConditionsCreated: 11/5/2021 12:00:00 AMLast Editorial Review: 11/5/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 5, 2021 Category: Cancer & Oncology Source Type: news

Changing Cancer Care, So Patients No Longer Feel Like a Number
“Having cancer is terrifying. It’s scary. And going to the hospital—I really felt like a number,” says Marc Hulett, who was diagnosed with prostate cancer in 2004. Hulett had surgery to remove his prostate and has been on hormone therapy for 17 years. Every three months, he gets a blood test to monitor his progress, but he no longer feels like a number. He drives from his home in Palm Springs, Calif., to Los Angeles—which can take up to six hours—to see his oncologist, Dr. David Agus, at the Ellison Institute for Transformative Medicine. As the name suggests, the Institute isn’t ju...
Source: TIME: Health - November 3, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthscienceclimate Source Type: news

Breast MRI during workup of DCIS can spur anxiety in women
Women undergoing breast MRI for evaluation of ductal carcinoma in situ experienc...Read more on AuntMinnie.comRelated Reading: Contrast-enhanced mammography can predict underestimated DCIS Prediction models can reduce false positives in breast MRI screening DCIS shows as nonmass enhancement on breast MRI Health practitioners overestimate likelihood of disease, study says Women with DCIS have 3x the risk of breast cancer death (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2021 Category: Radiology Source Type: news

Study Supports Opdivo as Second-Line Mesothelioma Treatment
When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line treatment. The first phase III, placebo-controlled, double-blind clinical trial studying the safety and efficacy of Opdivo, the immunotherapy drug known generically as nivolumab, has raised the level of confidence in this option for patients with relapsed disease. “The evidence is robust, the survival significant,” Dr. Dean Fennell, chair of Thoracic Medical Oncology, University of Leicester and University Hospitals in the United Kingdom, told T...
Source: Asbestos and Mesothelioma News - November 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Risk of HCC in Hepatitis B and D Virus Co-infected Patients Risk of HCC in Hepatitis B and D Virus Co-infected Patients
Does coinfection with hepatitis D virus further increase the risk of hepatocellular carcinoma in patients with hepatitis B infection?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 1, 2021 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Sharing Mayo Clinic: 'Sneaky' cancer spurs mom and daughter to action
When Lisa Pitre, a Mayo Clinic speech pathologist from Jacksonville, Florida, went in for a routine mammogram in summer 2019, nothing on her imaging was concerning. By October, though, Lisa was diagnosed with stage 4 invasive lobular carcinoma, an aggressive type of breast cancer. "I learned that 20% of breast cancers are not detected on mammograms, and mine was one of those," says the 53-year-old mother of two, noting that her cancer was found only after an MRI… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 30, 2021 Category: Databases & Libraries Source Type: news

What Is Life Expectancy of Renal Cell Carcinoma
What Is the Life Expectancy of Someone with Renal Cell Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 27, 2021 Category: General Medicine Source Type: news

Medivir Appoints Jens Lindberg as Chief Executive Officer
STOCKHOLM, Oct. 25, 2021 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharma... Biopharmaceuticals, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2021 Category: Pharmaceuticals Source Type: news

Mystery of the environmental triggers for cancer deepens
Study shows that our knowledge of why tumours form is still inadequateScientists will have to rethink howenvironmental triggers allow tumours to form and develop, one of Britain ’s leading cancer experts warned last week. Michael Stratton, director of the Wellcome Sanger Institute, said recent results from an international cancer research study – which aimed to pinpoint environmental triggers involved in oeosophageal cancer – indicated current scientific understanding of tumour formation was inadequate.The research – on a type known as oesophageal squamous cell carcinoma – was aimed at uncover...
Source: Guardian Unlimited Science - October 24, 2021 Category: Science Authors: Robin McKie Tags: Cancer research Medical research UK news Science Source Type: news

Bringing WISDOM to Breast Cancer Care
Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - October 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news

Skin Cancer App Fails to Identify Rare, Aggressive Cancers
Sensitivity and specificity for detecting Merkel cell carcinoma and amelanotic melanoma was 79.4 and 37.7 percent, respectively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 14, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Pathology, Conference News, Source Type: news

Interventions for Basal Cell Carcinoma Interventions for Basal Cell Carcinoma
Which are the most effective interventions for primary basal cell carcinoma? This systemic review examined the current evidence for both surgical and non-surgical treatments.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 13, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Renal Cell Carcinoma Highlights From ESMO 2021 Renal Cell Carcinoma Highlights From ESMO 2021
Dr Brian Rini, of Vanderbilt University, discusses key RCC abstracts from ESMO 2021, including data on efficacy and quality-of-life endpoints from the STAR, PRISM, and KEYNOTE-564 trials.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
WOBURN, Mass., Oct. 11, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIR... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2021 Category: Pharmaceuticals Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Incidence of Keratinocyte Carcinoma Up From 2003 to 2017
Incidence rate higher for women younger than 55 years and for men aged 55 years and older; mortality higher for men (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 4, 2021 Category: Cancer & Oncology Tags: Dermatology, Gynecology, Internal Medicine, Oncology, Journal, Source Type: news

Hepatocellular carcinoma screening in cirrhotic patients is worth it in Australia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

A Clinical and Biological Review of Keratoacanthoma A Clinical and Biological Review of Keratoacanthoma
Can keratoacanthomas be differentiated from cutaneous squamous cell carcinoma? This review compares the pathophysiology and clinical characteristics of the two, suggesting they are distinct entities.The British Journal of Dermatology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2021 Category: Surgery Tags: Dermatology Journal Article Source Type: news

Use Live Donors for Liver Transplants for HCC Patients Use Live Donors for Liver Transplants for HCC Patients
For patients with hepatocelluar carcinoma (HCC), liver transplant from a live donor improves survival and frees up organs from deceased donors for other patients on the long waiting list.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Risk factors associated with suicide among esophageal carcinoma patients from 1975 to 2016 - Chen C, Lin H, Xu F, Liu J, Cai Q, Yang F, Lv L, Jiang Y.
Throughout the world, esophageal cancer patients had a greater suicidal risk compared with ordinary people. Thus, we aimed to affirm suicide rates, standardized mortality rates, and underlying suicide-related risk factors of esophageal cancer patients. Pat... (Source: SafetyLit)
Source: SafetyLit - September 24, 2021 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news

Watchful Waiting in BCC: Which Patients Can Benefit? Watchful Waiting in BCC: Which Patients Can Benefit?
Some patients with basal cell carcinoma (BCC) may not need treatment. New data reveal who those patients likely are.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 20, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Wake Forest School of Medicine Research shows radio-wave therapy is safe for liver cancer patients and improves overall survival
Researchers at Wake Forest School of Medicine have shown that a targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The therapy also showed a benefit in overall survival. The study findings appear online in 4Open, a journal published by EDP Sciences. “HCC accounts for nearly 90% of all liver cancers, and current survival rates are between six and 20 months,” said Dr. Boris Pasche, chair of cancer… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 15, 2021 Category: Biotechnology Authors: Atrium Health Wake Forest Baptist Source Type: news

Wake Forest School of Medicine Research shows radio-wave therapy is safe for liver cancer patients and improves overall survival
Researchers at Wake Forest School of Medicine have shown that a targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The therapy also showed a benefit in overall survival. The study findings appear online in 4Open, a journal published by EDP Sciences. “HCC accounts for nearly 90% of all liver cancers, and current survival rates are between six and 20 months,” said Dr. Boris Pasche, chair of cancer… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 15, 2021 Category: American Health Authors: Atrium Health Wake Forest Baptist Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

PET identifies early responders to liver cancer treatment
PET imaging can predict how liver cancer patients are going to respond earl...Read more on AuntMinnie.comRelated Reading: AI can identify hepatocellular carcinoma on liver CT exams FCH-PET shines in guiding parathyroid surgery Study evaluates safety of new liver cancer treatment Sirtex launches study to assess SIR-Spheres for HCC US microbubble destruction may improve TARE response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 10, 2021 Category: Radiology Source Type: news

Fraction of Cirrhosis and HCC Attributable to Hepatitis B and C Fraction of Cirrhosis and HCC Attributable to Hepatitis B and C
This study assessed a protocol developed by WHO to collect data on the worldwide fraction of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C. How might it be improved?Journal of Viral Hepatitis (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2021 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients
Might nonselective beta-blockers such as carvedilol, nadolol, and propranolol decrease the risk of hepatocellular carcinoma among patients with cirrhosis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Human Papillomavirus-Associated Head and Neck Cancer Human Papillomavirus-Associated Head and Neck Cancer
Review the epidemiology, screening, presentation, diagnosis, prognosis, and prevention of HPV-positive oropharyngeal squamous cell carcinoma, with a focus on the primary care provider's role.Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Guidance Issued for Preventing Cutaneous SCC in Solid Organ Recipients
WEDNESDAY, Sept. 1, 2021 -- In a consensus statement published online Sept. 1 in JAMA Dermatology, recommendations are presented for prevention strategies for cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2021 Category: Pharmaceuticals Source Type: news

Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
SHANGHAI, China, and REDWOOD CITY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

Effect of NSAIDs and APT on Incidence and Recurrence of HCC Effect of NSAIDs and APT on Incidence and Recurrence of HCC
This study investigated whether NSAIDs or aspirin might have an impact on hepatocellular carcinoma incidence or recurrence among high-risk persons with chronic liver disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

High Success Rates With Down-Staging of Liver Cancer Prior to Transplant High Success Rates With Down-Staging of Liver Cancer Prior to Transplant
Down-staging of hepatocellular carcinoma prior to liver transplant based on UNOS criteria is successful most of the time using either chemoembolization or Y-90 radioembolization, new research indicates.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 30, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Quality of Anatomic Staging of Breast Carcinoma Quality of Anatomic Staging of Breast Carcinoma
By comparing pathologic and clinical staging data, this study aimed to assess the accuracy of clinical breast cancer anatomic staging at US hospitals.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA approves nivolumab for adjuvant treatment of urothelial carcinoma
Oncology (Cancer) FDA approves nivolumab for adjuvant treatment of urothelial carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 20, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) August 20, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for intravenous use) was approved by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 20, 2021 Category: Drugs & Pharmacology Source Type: news

Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
Rate of disease - free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 19, 2021 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
THURSDAY, Aug. 19, 2021 -- For patients with clear-cell renal cell carcinoma at high risk for recurrence after nephrectomy, adjuvant therapy with pembrolizumab improves disease-free survival, according to a study published in the Aug. 19 issue of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2021 Category: Pharmaceuticals Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

' Dawn of a New Era' in the Treatment of Renal Cell Carcinoma'Dawn of a New Era' in the Treatment of Renal Cell Carcinoma
Adjuvant pembrolizumab demonstrates significant disease-free survival benefit without excess toxicity in patients at high risk of recurrence.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Social Security Adds Pericardial Mesothelioma to Disabilities List
The U.S. Social Security Administration has added pericardial mesothelioma to its Compassionate Allowances list, accelerating the disabilities application process for this very rare cancer. Its decision was prompted by the work of Missy Miller, medical outreach director at The Mesothelioma Center. She made the request with the Social Security disability office almost a year ago on behalf of a patient. The Compassionate Allowances program is reserved for severe medical diseases and conditions that automatically meet Social Security standards for disability benefits. It cuts short the often drawn-out application proces...
Source: Asbestos and Mesothelioma News - August 18, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news